Skip to Content
Find More Like This
Return to Search

Chimeric OspA genes, proteins and methods of use thereof

United States Patent

9,895,434
February 20, 2018
View the Complete Patent at the US Patent & Trademark Office
The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.
Crowe; Brian A. (Leobendorf, AT), Livey; Ian (Vienna, AT), O'Rourke; Maria (Wiener Neudorf, AT), Schwendinger; Michael (Neusiedl Am See, AT), Dunn; John J. (Bellport, NY), Luft; Benjamin J. (Riverhead, NY)
Research Foundation of the State University of New York (Amherst, NY), Brookhaven Science Associates, LLC (Upton, NY)
15/ 049,438
February 22, 2016
STATEMENT OF RIGHTS UNDER FEDERALLY SPONSORED RESEARCH This invention was made with Government support under Prime Contract No. DE-SC0012704, awarded by the Department of Energy. The Government has certain rights in this invention.